Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013 (2013), Article ID 689591, 9 pages
http://dx.doi.org/10.1155/2013/689591
Review Article

Clinical, Biological, and Imaging Features of Monogenic Alzheimer’s Disease

Clinica Neurologica, Università degli Studi di Brescia, Pza Spedali Civili, 1-25100 Brescia, Italy

Received 25 September 2013; Accepted 4 November 2013

Academic Editor: Benedetta Nacmias

Copyright © 2013 Andrea Pilotto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Goate, M.-C. Chartier-Harlin, M. Mullan et al., “Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease,” Nature, vol. 349, no. 6311, pp. 704–706, 1991. View at Publisher · View at Google Scholar · View at Scopus
  2. E. I. Rogaev, R. Sherrington, E. A. Rogaeva et al., “Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene,” Nature, vol. 376, no. 6543, pp. 775–778, 1995. View at Google Scholar · View at Scopus
  3. R. Sherrington, E. I. Rogaev, Y. Liang et al., “Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease,” Nature, vol. 375, no. 6534, pp. 754–760, 1995. View at Google Scholar · View at Scopus
  4. R. J. Bateman, P. S. Aisen, B. De Strooper et al., “Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease,” Alzheimer's Research and Therapy, vol. 3, no. 1, article 1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. R. J. Harvey, M. Skelton-Robinson, and M. N. Rossor, “The prevalence and causes of dementia in people under the age of 65 years,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 74, no. 9, pp. 1206–1209, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Ikejima, F. Yasuno, K. Mizukami, M. Sasaki, S. Tanimukai, and T. Asada, “Prevalence and causes of early-onset dementia in japan: a population-based study,” Stroke, vol. 40, no. 8, pp. 2709–2714, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Garre-Olmo, D. Genís Batlle, M. Del Mar Fernández et al., “Incidence and subtypes of early-onset dementia in a geographically defined general population,” Neurology, vol. 75, no. 14, pp. 1249–1255, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Yokota, K. Sasaki, Y. Fujisawa et al., “Frequency of early and late-onset dementias in a Japanese memory disorders clinic,” European Journal of Neurology, vol. 12, no. 10, pp. 782–790, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Mercy, J. R. Hodges, K. Dawson, R. A. Barker, and C. Brayne, “Incidence of early-onset dementias in Cambridgeshire, United Kingdom,” Neurology, vol. 71, no. 19, pp. 1496–1499, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. G. Papageorgiou, T. Kontaxis, A. Bonakis, N. Kalfakis, and D. Vassilopoulos, “Frequency and causes of early-onset dementia in a tertiary referral center in athens,” Alzheimer Disease and Associated Disorders, vol. 23, no. 4, pp. 347–351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Borroni, A. Alberici, M. Grassi et al., “Prevalence and demographic features of early-onset neurodegenerative dementia in Brescia County, Italy,” Alzheimer Disease and Associated Disorders, vol. 25, no. 4, pp. 341–344, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Campion, C. Dumanchin, D. Hannequin et al., “Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum,” American Journal of Human Genetics, vol. 65, no. 3, pp. 664–670, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Cruts, C. M. Van Duijn, H. Backhovens et al., “Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease,” Human Molecular Genetics, vol. 7, no. 1, pp. 43–51, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. J. C. Janssen, J. A. Beck, T. A. Campbell et al., “Early onset familial Alzheimer's disease: mutation frequency in 31 families,” Neurology, vol. 60, no. 2, pp. 235–239, 2003. View at Google Scholar · View at Scopus
  15. G. Raux, L. Guyant-Maréchal, C. Martin et al., “Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update,” Journal of Medical Genetics, vol. 42, no. 10, pp. 793–795, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Kasuga, T. Shimohata, A. Nishimura et al., “Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 9, pp. 1050–1052, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Sleegers, N. Brouwers, I. Gijselinck et al., “APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy,” Brain, vol. 129, no. 11, pp. 2977–2983, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. E. S. Blom, J. Viswanathan, L. Kilander et al., “Low prevalence of APP duplications in Swedish and Finnish patients with early-onset Alzheimer's disease,” European Journal of Human Genetics, vol. 16, no. 2, pp. 171–175, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Braak and E. Braak, “Neuropathological stageing of Alzheimer-related changes,” Acta Neuropathologica, vol. 82, no. 4, pp. 239–259, 1991. View at Google Scholar · View at Scopus
  20. B. T. Hyman, “Amyloid-dependent and amyloid-independent stages of alzheimer disease,” Archives of Neurology, vol. 68, no. 8, pp. 1062–1064, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. B. De Strooper, P. Saftig, K. Craessaerts et al., “Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein,” Nature, vol. 391, no. 6665, pp. 387–390, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Cao and T. C. Sudhof, “A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60,” Science, vol. 293, no. 5534, pp. 115–120, 2001. View at Google Scholar · View at Scopus
  23. R. Vassar, B. D. Bennett, S. Babu-Khan et al., “β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE,” Science, vol. 286, no. 5440, pp. 735–741, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Citron, T. S. Diehl, G. Gordon, A. L. Biere, P. Seubert, and D. J. Selkoe, “Evidence that the 42- and 40-amino acid forms of amyloid β protein are generated from the β-amyloid precursor protein by different protease activities,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 23, pp. 13170–13175, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Tomiyama, T. Nagata, H. Shimada et al., “A new amyloid β variant favoring oligomerization in Alzheimer's-type dementia,” Annals of Neurology, vol. 63, no. 3, pp. 377–387, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Tandon, E. Rogaeva, M. Mullan, and P. H. St. George-Hyslop, “Molecular genetics of Alzheimer's disease: the role of β-amyloid and the presenilins,” Current Opinion in Neurology, vol. 13, no. 4, pp. 377–384, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Edbauer, E. Winkler, J. T. Regula, B. Pesold, H. Steiner, and C. Haass, “Reconstitution of γ-secretase activity,” Nature Cell Biology, vol. 5, no. 5, pp. 486–488, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Di Fede, M. Catania, M. Morbin et al., “A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis,” Science, vol. 323, no. 5920, pp. 1473–1477, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Zekanowski and U. Wojda, “Aneuploidy, chromosomal missegregation, and cell cycle reentry in Alzheimer's disease,” Acta Neurobiologiae Experimentalis, vol. 69, no. 2, pp. 232–253, 2009. View at Google Scholar · View at Scopus
  30. A. Rovelet-Lecrux, D. Hannequin, G. Raux et al., “APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy,” Nature Genetics, vol. 38, no. 1, pp. 24–26, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Cabrejo, L. Guyant-Maréchal, A. Laquerrière et al., “Phenotype associated with APP duplication in five families,” Brain, vol. 129, no. 11, pp. 2966–2976, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Jonsson, J. K. Atwal, S. Steinberg et al., “A mutation in APP protects against Alzheimer's disease and age-related cognitive decline,” Nature, vol. 488, pp. 96–99, 2012. View at Google Scholar
  33. D. Scheuner, C. Eckman, M. Jensen et al., “Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease,” Nature Medicine, vol. 2, no. 8, pp. 864–870, 1996. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Kumar-Singh, J. Theuns, B. Van Broeck et al., “Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40,” Human Mutation, vol. 27, no. 7, pp. 686–695, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Bentahir, O. Nyabi, J. Verhamme et al., “Presenilin clinical mutations can affect γ-secretase activity by different mechanisms,” Journal of Neurochemistry, vol. 96, no. 3, pp. 732–742, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. A. J. Larner and M. Doran, “Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene,” Journal of Neurology, vol. 253, no. 2, pp. 139–158, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. A. J. Larner, “Presenilin-1 mutations in Alzheimer's disease: an update on genotype-phenotype relationships,” Journal of Alzheimer's Disease, vol. 37, no. 4, pp. 653–659, 2013. View at Publisher · View at Google Scholar
  38. W. T. Kimberly, M. J. LaVoie, B. L. Ostaszewski, W. Ye, M. S. Wolfe, and D. J. Selkoe, “γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6382–6387, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. M. H. Park, D. Y. Choi, H. W. Jin et al., “Mutant presenilin 2 increases β-secretase activity through reactive oxygen species-dependent activation of extracellular signal-regulated kinase,” Journal of Neuropathology and Experimental Neurology, vol. 71, no. 2, pp. 130–139, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. B. J. Snider, J. Norton, M. A. Coats et al., “Novel presenilin 1 mutation (S170F) causing Alzheimer disease with lewy bodies in the third decade of life,” Archives of Neurology, vol. 62, no. 12, pp. 1821–1830, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Pastor, C. M. Roe, A. Villegas et al., “Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred,” Annals of Neurology, vol. 54, no. 2, pp. 163–169, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Bernardi, M. Gallo, M. Anfossi et al., “Role of TOMM40 rs10524523 polymorphism in onset of Alzheimer's disease caused by the PSEN1 M146L mutation,” Journal of Alzheimer's Disease, vol. 37, pp. 285–289, 2013. View at Google Scholar
  43. T. D. Bird, E. Levy-Lahad, P. Poorkaj et al., “Wide range in age of onset for chromosome 1-related familial Alzheimer's disease,” Annals of Neurology, vol. 40, no. 6, pp. 932–936, 1996. View at Publisher · View at Google Scholar · View at Scopus
  44. E. K. Warrington, S. K. Agnew, A. M. Kennedy, and M. N. Rossor, “Neuropsychological profiles of familial Alzheimer's disease associated with mutations in the presenilin 1 and amyloid precursor protein genes,” Journal of Neurology, vol. 248, no. 1, pp. 45–50, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. A. K. Godbolt, L. Cipolotti, H. Watt, N. C. Fox, J. C. Janssen, and M. N. Rossor, “The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort,” Archives of Neurology, vol. 61, no. 11, pp. 1743–1748, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. N. C. Fox, E. K. Warrington, A. L. Seiffer, S. K. Agnew, and M. N. Rossor, “Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study,” Brain, vol. 121, no. 9, pp. 1631–1639, 1998. View at Publisher · View at Google Scholar · View at Scopus
  47. R. J. Bateman, C. Xiong, T. L. Benzinger et al., “Clinical and biomarker changes in dominantly inherited Alzheimer's disease,” The New England Journal of Medicine, vol. 367, pp. 795–804, 2012. View at Google Scholar
  48. A. Ardila, F. Lopera, M. Rosselli et al., “Neuropsychological profile of a large kindred with familial Alzheimer's disease caused by the E280A single presenilin-1 mutation,” Archives of Clinical Neuropsychology, vol. 15, no. 6, pp. 515–528, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Jimenez-Escrig, A. Rabano, C. Guerrero et al., “New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism,” European Journal of Neurology, vol. 11, no. 10, pp. 663–669, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. E. J. Sitek, E. Narozanska, B. Peplonska et al., “A patient with posterior cortical atrophy possesses a novel mutation in the presenilin 1 gene,” PloS ONE, vol. 8, Article ID e61074, 2013. View at Google Scholar
  51. B. Borroni, A. Pilotto, C. Bonvicini et al., “Atypical presentation of a novel Presenilin 1 R377W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy,” Neurological Sciences, vol. 33, no. 2, pp. 375–378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Watanabe, D. Xia, T. Kanekiyo, R. J. Kelleher, and J. Shen, “Familial frontotemporal dementia-associated Presenilin-1 c.548G>T mutation causes decreased mRNA expression and reduced presenilin function in knock-in mice,” Journal of Neuroscience, vol. 32, no. 15, pp. 5085–5096, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Padovani, E. Premi, A. Pilotto et al., “Overlap between frontotemporal dementia and Alzheimer's disease: cerebrospinal fluid pattern and neuroimaging study,” Journal of Alzheimer's Disease, vol. 36, pp. 49–55, 2013. View at Google Scholar
  54. D. Sepulveda-Falla, M. Glatzel, and F. Lopera, “Phenotypic profile of early-onset familial Alzheimer's disease caused by presenilin-1 E280A mutation,” Journal of Alzheimer's Disease, vol. 32, pp. 1–12, 2012. View at Google Scholar
  55. A. Alberici, C. Bonato, B. Borroni et al., “Dementia, delusions and seizures: storage disease or genetic AD?” European Journal of Neurology, vol. 14, no. 9, pp. 1057–1059, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. A. J. Larner, “Presenilin-1 mutation Alzheimer's disease: a genetic epilepsy syndrome?” Epilepsy and Behavior, vol. 21, no. 1, pp. 20–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Minkeviciene, S. Rheims, M. B. Dobszay et al., “Amyloid β-induced neuronal hyperexcitability triggers progressive epilepsy,” Journal of Neuroscience, vol. 29, no. 11, pp. 3453–3462, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Ishikawa, Y.-S. Piao, A. Miyashita et al., “A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease,” Annals of Neurology, vol. 57, no. 3, pp. 429–434, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Piscopo, G. Marcon, M. R. Piras et al., “A novel PSEN2 mutation associated with a peculiar phenotype,” Neurology, vol. 70, no. 17, pp. 1549–1554, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Karlstrom, W. S. Brooks, J. B. J. Kwok et al., “Variable phenotype of Alzheimer's disease with spastic paraparesis,” Journal of Neurochemistry, vol. 104, no. 3, pp. 573–583, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Verkkoniemi, M. Somer, J. O. Rinne et al., “Variant Alzheimer's disease with spastic paraparesis: clinical characterization,” Neurology, vol. 54, no. 5, pp. 1103–1109, 2000. View at Google Scholar · View at Scopus
  62. T. Revesz, J. L. Holton, T. Lashley et al., “Sporadic and familial cerebral amyloid angiopathies,” Brain Pathology, vol. 12, no. 3, pp. 343–357, 2002. View at Google Scholar · View at Scopus
  63. R. J. Ellis, J. M. Olichney, L. J. Thal et al., “Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, part XV,” Neurology, vol. 46, no. 6, pp. 1592–1596, 1996. View at Google Scholar · View at Scopus
  64. E. Levy, M. D. Carman, I. J. Fernandez-Madrid et al., “Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type,” Science, vol. 248, no. 4959, pp. 1124–1126, 1990. View at Google Scholar · View at Scopus
  65. M. Bornebroek, J. Haan, M. L. C. Maat-Schieman, S. G. Van Duinen, and R. A. C. Roos, “Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): I—a review of clinical, radiologic and genetic aspects,” Brain Pathology, vol. 6, no. 2, pp. 111–114, 1996. View at Google Scholar · View at Scopus
  66. B. F. Jones, J. Barnes, H. B. M. Uylings et al., “Differential regional atrophy of the cingulate gyrus in Alzheimer disease: a volumetric MRI study,” Cerebral Cortex, vol. 16, no. 12, pp. 1701–1708, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. N. C. Fox, W. R. Crum, R. I. Scahill, J. M. Stevens, J. C. Janssen, and M. N. Rossor, “Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images,” The Lancet, vol. 358, no. 9277, pp. 201–205, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. G. C. Gregory, V. Macdonald, P. R. Schofield, J. J. Kril, and G. M. Halliday, “Differences in regional brain atrophy in genetic forms of Alzheimer's disease,” Neurobiology of Aging, vol. 27, no. 3, pp. 387–393, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Ginestroni, M. Battaglini, R. Della Nave et al., “Early structural changes in individuals at risk of familial Alzheimer's disease: a volumetry and magnetization transfer MR imaging study,” Journal of Neurology, vol. 256, no. 6, pp. 925–932, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. G. B. Frisoni, M. Pievani, C. Testa et al., “The topography of grey matter involvement in early and late onset Alzheimer's disease,” Brain, vol. 130, no. 3, pp. 720–730, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. L. G. Apostolova, K. S. Hwang, L. D. Medina et al., “Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease,” Dementia and Geriatric Cognitive Disorders, vol. 32, no. 2, pp. 118–125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. R. I. Scahill, G. R. Ridgway, J. W. Bartlett et al., “Genetic influences on atrophy patterns in familial Alzheimer's Disease: a comparison of APP and PSEN1 mutations,” Journal of Alzheimer's Disease, vol. 35, pp. 199–212, 2013. View at Google Scholar
  73. P. B. Gorelick, A. Scuteri, S. E. Black et al., “Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association,” Stroke, vol. 42, no. 9, pp. 2672–2713, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. F. Fazekas, R. Kleinert, G. Roob et al., “Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds,” American Journal of Neuroradiology, vol. 20, no. 4, pp. 637–642, 1999. View at Google Scholar · View at Scopus
  75. E. M. Haacke, Z. S. DelProposto, S. Chaturvedi et al., “Imaging cerebral amyloid angiopathy with susceptibility-weighted imaging,” American Journal of Neuroradiology, vol. 28, no. 2, pp. 316–317, 2007. View at Google Scholar · View at Scopus
  76. S. M. Greenberg, M. W. Vernooij, C. Cordonnier et al., “Cerebral microbleeds: a guide to detection and interpretation,” The Lancet Neurology, vol. 8, no. 2, pp. 165–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. S. D. Friedman, D. W. W. Shaw, G. Ishak, A. L. Gropman, and R. P. Saneto, “The use of neuroimaging in the diagnosis of mitochondrial disease,” Developmental Disabilities Research Reviews, vol. 16, no. 2, pp. 129–135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. I. Zerr, K. Kallenberg, D. M. Summers et al., “Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease,” Brain, vol. 132, pp. 2659–2668, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Autti, R. Joensuu, and L. Åberg, “Decreased T2 signal in the thalami may be a sign of lysosomal storage disease,” Neuroradiology, vol. 49, no. 7, pp. 571–578, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. N. I. Bohnen, D. S. W. Djang, K. Herholz, Y. Anzai, and S. Minoshima, “Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature,” Journal of Nuclear Medicine, vol. 53, no. 1, pp. 59–71, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Herholz, H. Schopphoff, M. Schmidt et al., “Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease,” Journal of Nuclear Medicine, vol. 43, no. 1, pp. 21–26, 2002. View at Google Scholar · View at Scopus
  82. T. Nihashi, H. Yatsuya, K. Hayasaka et al., “Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients,” Radiation Medicine, vol. 25, no. 6, pp. 255–262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. V. L. Villemagne, S. Ataka, T. Mizuno et al., “High striatal amyloid β-peptide deposition across different autosomal Alzheimer disease mutation types,” Archives of Neurology, vol. 66, no. 12, pp. 1537–1544, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Herholz and K. Ebmeier, “Clinical amyloid imaging in Alzheimer's disease,” The Lancet Neurology, vol. 10, no. 7, pp. 667–670, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. G. D. Rabinovici, H. J. Rosen, A. Alkalay et al., “Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD,” Neurology, vol. 77, no. 23, pp. 2034–2042, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. W. Maetzler, I. Liepelt, M. Reimold et al., “Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics,” Neurobiology of Disease, vol. 34, no. 1, pp. 107–112, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. C. E. Leyton, V. L. Villemagne, S. Savage et al., “Subtypes of progressive aphasia: application of the international consensus criteria and validation using β-amyloid imaging,” Brain, vol. 134, no. 10, pp. 3030–3043, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. J. M. Ringman, S. G. Younkin, D. Pratico et al., “Biochemical markers in persons with preclinical familial Alzheimer disease,” Neurology, vol. 71, no. 2, pp. 85–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. L. M. Shaw, H. Vanderstichele, M. Knapik-Czajka et al., “Cerebrospinal fluid biomarker signature in alzheimer's disease neuroimaging initiative subjects,” Annals of Neurology, vol. 65, no. 4, pp. 403–413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. A. M. Fagan, M. A. Mintun, R. H. Mach et al., “Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta;42 in humans,” Annals of Neurology, vol. 59, no. 3, pp. 512–519, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. E. M. Reiman, Y. T. Quiroz, A. S. Fleisher et al., “Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study,” The Lancet Neurology, vol. 11, pp. 1048–1056, 2012. View at Google Scholar
  92. B. Borroni, E. Premi, C. Agosti et al., “CSF Alzheimer's disease-like pattern in corticobasal syndrome: evidence for a distinct disorder,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 82, no. 8, pp. 834–838, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. A. Kas, O. Uspenskaya, F. Lamari et al., “Distinct brain perfusion pattern associated with CSF biomarkers profile in primary progressive aphasia,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 83, pp. 695–698, 2012. View at Google Scholar
  94. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg, “Cerebrospinal fluid and plasma biomarkers in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 3, pp. 131–144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. J. Beck, A. Pittman, G. Adamson et al., “Validation of next-generation sequencing technologies in genetic diagnosis of dementia,” Neurobiol Aging, vol. 35, no. 1, pp. 261–265, 2014. View at Google Scholar
  96. A. Antonell, A. Lladó, J. Altirriba et al., “A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease,” Neurobiol Aging, vol. 34, no. 7, pp. 1772–1778, 2013. View at Google Scholar
  97. E. Milanesi, C. Bonvicini, A. Alberici et al., “Molecular signature of disease onset in Granulin mutation carriers: a gene expression analysis study,” Neurobiol Aging, vol. 34, no. 7, pp. 1837–1845, 2013. View at Google Scholar
  98. A. S. Fleisher, K. Chen, Y. T. Quiroz et al., “Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study,” The Lancet Neurology, vol. 11, pp. 1057–1065, 2012. View at Google Scholar
  99. J. M. Ringman, J. O'Neill, D. Geschwind et al., “Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations,” Brain, vol. 130, no. 7, pp. 1767–1776, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. G. J. Lee, P. H. Lu, L. D. Medina et al., “Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 84, pp. 154–162, 2013. View at Google Scholar
  101. N. S. Ryan, S. Keihaninejad, T. J. Shakespeare et al., “Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease,” Brain, vol. 136, pp. 1399–1414, 2013. View at Google Scholar
  102. Y. T. Quiroz, C. E. Stern, E. M. Reiman et al., “Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 84, pp. 556–561, 2013. View at Google Scholar
  103. D. Cash, G. Ridgway, Y. Liang et al., “On behalf of the Dominantly Inherited Alzheimer Network (DIAN). The pattern of atrophy in familial alzheimer disease: volumetric MRI results from the DIAN Study,” Neurology, vol. 81, no. 16, pp. 1425–1433, 2013. View at Publisher · View at Google Scholar
  104. J. P. Chhatwal, A. P. Schultz, K. Johnson et al., “Impaired default network functional connectivity in autosomal dominant Alzheimer disease,” Neurology, vol. 81, pp. 736–744, 2013. View at Google Scholar
  105. B. Dubois, H. H. Feldman, C. Jacova et al., “Revising the definition of Alzheimer's disease: a new lexicon,” The Lancet Neurology, vol. 9, no. 11, pp. 1118–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus